Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis (Q36580568)

15 August 2017

1 reference

title

Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis (English)

1 reference

15 August 2017

1 reference

1 reference

3

1 reference

15 August 2017

Jean-Charles Fruchart

series ordinal

2

object named as

Jean-Charles Fruchart

0 references

Benoit Pourcet

object named as

Benoit Pourcet

series ordinal

1

0 references

Corine Glineur

series ordinal

4

object named as

Corine Glineur

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

1 reference

15 August 2017

11

1 reference

15 August 2017

379-401

1 reference

15 August 2017

3

1 reference

Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Fatty acids, lipotoxicity and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPARgamma and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Current therapeutic options in type 2 diabetes mellitus: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The nicotinic acid receptor--a new mechanism for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Molecular identification of high and low affinity receptors for nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Increased sensitivity of fat cell adenylate cyclase to stimulatory agonists during fasting is not related to impaired inhibitory coupling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The role of fibric acids in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptors: nuclear control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPAR delta: a dagger in the heart of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPARalpha).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

C/EBP binding activity to site F of the rat GLUT2 glucose transporter gene promoter is attenuated by c-Jun in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Regulation of Cbl-associated protein/Cbl pathway in muscle and adipose tissues of two animal models of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Protein phosphatase-1 and insulin action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Mapping of early signaling events in tumor necrosis factor-alpha -mediated lipolysis in human fat cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Elevated Levels of Interleukin 6 Are Reduced in Serum and Subcutaneous Adipose Tissue of Obese Women after Weight Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Interleukin-6 induces cellular insulin resistance in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

High lipoprotein lipase activity increases insulin sensitivity in transgenic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPARdelta regulates glucose metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Selective PPARgamma modulators with improved pharmacological profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor γ Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Synthesis and biological activity of novel alpha-substituted beta-phenylpropionic acids having pyridin-2-ylphenyl moiety as antihyperglycemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Synthesis and evaluation of azaindole-alpha-alkyloxyphenylpropionic acid analogues as PPARalpha/gamma agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious gluco

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome proliferator-activated receptor alpha,gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Glucose Down-regulates the Expression of the Peroxisome Proliferator-activated Receptor-α Gene in the Pancreatic β-Cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.379

10.1517/14728214.11.3.379

21 January 2018

Identifiers

DOI

1 reference

release_ee4lxu4ks5gxlk6jd6gjl427ke

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ee4lxu4ks5gxlk6jd6gjl427ke

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference